The latest data from an early Phase I study includes an analysis from 20 additional people detailing how the vaccine performed in older adults. The analysis looked at subjects given the 100-microgram dose being tested in the much larger Phase III trial. Moderna said the immune responses in those aged between ages 56 and 70, above age 70 and those 18 to 55-years-old were similar. …read more
Source:: Yahoo Finance
